700 patients109,892 observations180 daysLIVE
Decision memos written from the data: segments, regimens, diagnostics worth adding at baseline, combinations that keep patients. Rebuilt from the learning layer on every visit.

What does this teach about the drug?

Synthetic demo data
Where it works best
META-24 works best in Poor metabolizer

32% of Poor metabolizer patients (n 149) are responding and under the churn line, against 42% overall. Enrich the next cohort and the label language for this segment; the biology is dna · drug exposure.

Evidence: 149 patients · retained response 32% vs 42%
Who needs a different regimen
Adherence < 60% patients need a different regimen

52% carry toxicity ≥ 50 today (n 79). Dose-timing and meal-timing interventions are the cheapest test: in the data, taking the dose after a meal and low-residue meals on dosing days are the primitives with the largest GI effect. A dose-timing sub-study in this segment is a small, fast trial.

Evidence: toxicity ≥ 50 in 52% of the segment
Combination candidate
META-24 + DT-01 keeps 84% of the patients it is given to

Dosing / Timing Recommendation is the protocol that turns an accepted recommendation into a retained patient most often (n 19). Bundling it into the companion from the first dosing day for every patient in the Poor metabolizer segment is the strongest strategy candidate in the data.

Evidence: DT-01 84% (n 19) · HY-01 78% (n 18) · GI-04 30% (n 73)
The drug, in one paragraph
What this says about the drug, in one paragraph

META-24 keeps 42% of patients responding and under the churn line. The ones it loses leave through side effects that are predictable from biology and daily behaviour, not from the molecule alone, and the same data shows which protocol brings each biology back. The strategic asset is therefore not the drug by itself but the drug plus its steering layer: diagnostics at baseline, a companion that carries the right content, and a model that keeps learning from every patient.

Evidence: 700 patients · 261 accepted actions · 0 learned rules

Rules behind these memos: Learning. Emerging patterns: Watch.